Key result
Pathological calmodulin variants associated with neurological symptoms impair the Ca2+/CaM-dependent inactivation of CaV1.3 and reduce the Ca2+-dependent facilitation of CaV2.1 channels in vitro.
Why the study?
The impact of calmodulin mutations on neurological function and voltage-gated calcium channel regulation beyond cardiac effects has not been fully explored.
Pathological calmodulin mutations disrupt Ca2+/CaM regulation of neuronal voltage-gated calcium channels (CaV1.3 and CaV2.1), providing a potential mechanism for the neurological comorbidities observed in patients with calmodulinopathies.
In vitro CaV dysregulation by calmodulin variants may link to neurological symptoms; leaves open in vivo relevance and therapeutic implications.
Calmodulinopathies are caused by mutations in calmodulin (CaM), and result in debilitating cardiac arrythmias such as long-QT syndrome (LQTS) and catecholaminergic polymorphic ventricular tachycardia (CPVT). In addition, many patients exhibit neurological comorbidities, including developmental delay and autism spectrum disorder. Until now, most work into these mutations has focused on cardiac effects, identifying impairment of Ca 2+ /CaM-dependent inactivation (CDI) of Ca V 1.2 channels as a major pathogenic mechanism. However, the impact of these mutations on neurological function has yet to be fully explored. CaM regulation of voltage-gated calcium channels (VGCCs) is a critical element of neuronal function, implicating multiple VGCC subtypes in the neurological pathogenesis of calmodulinopathies. Here, we explore the potential for pathological CaM variants to impair the Ca 2+ /CaM-dependent regulation of Ca V 1.3 and Ca V 2.1, both essential for neuronal function. We find that mutations in CaM can impair the CDI of Ca V 1.3 and reduce the Ca 2+ -dependent facilitation (CDF) of Ca V 2.1 channels. We find that mutations associated with significant neurological symptoms exhibit marked effects on Ca V 1.3 CDI, with overlapping but distinct impacts on Ca V 2.1 CDF. Moreover, while the majority of CaM variants demonstrated the ability to bind the IQ region of each channel, distinct differences were noted between Ca V 1.3 and Ca V 2.1, demonstrating distinct CaM interactions across the two channel subtypes. Further, C-domain CaM variants display a reduced ability to sense Ca 2+ when in complex with the Ca V IQ domains, explaining the Ca 2+ /CaM regulation deficits. Overall, these results support the possibility that disrupted Ca 2+ /CaM regulation of VGCCs may contribute to neurological pathogenesis of calmodulinopathies.
No takes yet. Share an insight, caveat, or question.
Hussey et al. (2024) studied Calmodulinopathies. Pathological Calmodulin (CaM) variants vs. Wild-type CaM was evaluated on Ca2+/CaM-dependent inactivation (CDI) of CaV1.3 and Ca2+-dependent facilitation (CDF) of CaV2.1. Pathological calmodulin variants associated with neurological symptoms impair the Ca2+/CaM-dependent inactivation of CaV1.3 and reduce the Ca2+-dependent facilitation of CaV2.1 channels in vitro.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: